Please login to the form below

Not currently logged in
Email:
Password:

Ergomed appoints Andrew Mackie as chief business officer

He is also inducted as executive director to the board

UK-based Ergomed has named Andrew Mackie as chief business officer and executive director to its board.

Mackie brings over 25 years of experience in pre clinical research, clinical and business development to the role and has held a number of senior R&D roles at Novartis and Sanofi. 

He joins from Lilly, where he was part of the business development team.

Miroslav Reljanovic, CEO at Ergomed, commented: “Over the past ten years, Andrew has worked with Ergomed as a consultant, and has been instrumental in developing the co-development business model, acting as lead negotiator on the partnerships signed to date. 

“His successful track record in drug development and deal making not only strengthens our capabilities as we continue to advance our co-development pipeline but ensures we have the right team in place as we look to expand through organic growth and acquisitions.”

After ten years in R&D, Mackie joined the UK biotech sector in 1997 at oncology specialist Antisoma, where he established the clinical development department and transitioned new molecules into development.

Ergomed provides specialised services to the pharma industry and the development of new drugs. 

6th July 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics